Clearing Chlamydia abortus infection in epithelial cells and primary human macrophages by use of antibiotics and the MDM2-p53-inhibitor nutlin-3

被引:3
|
作者
Diensthuber, Diana [1 ]
Simnacher, Ulrike [1 ]
Peters, Sarah [2 ]
Walther, Paul [3 ]
Essig, Andreas [1 ]
Hagemann, Jurgen Benjamin [1 ]
机构
[1] Ulm Univ Hosp, Inst Med Microbiol & Hyg, Ulm, Germany
[2] Ulm Univ Hosp, Dept Clin Chem, Ulm, Germany
[3] Ulm Univ, Cent Facil Electron Microscopy, Ulm, Germany
关键词
chlamydia abortus; azithromycin; doxycycline; nutlin-3; macrophage; ANTIMICROBIAL SUSCEPTIBILITY; AZITHROMYCIN; ACCUMULATION; ACTIVATION; MECHANISMS; EFFLUX; P53;
D O I
10.1016/j.diagmicrobio.2022.115715
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Chlamydia (C.) abortus is an emerging zoonotic pathogen. Since data on its antimicrobial susceptibility are lacking, we aimed to determine minimal inhibitory (MIC) and minimal bactericidal concentrations (MBC) for azithromycin and doxycycline in HeLa-cells and primary human macrophages (M1). We also examined the MDM2-p53-inhibitor nutlin-3, an anti-infective imidazoline analog. Azithromycin and doxycycline demonstrated MICs and MBCs equal or below their peak serum concentrations (PSC) after standard dosing in both cell types. While doxycycline exhibited an MIC 64-fold and an MBC 4-fold below its PSC in HeLa-cells, the MIC of azithromycin was 4-fold below, the MBC equal to the PSC. However, azithromycin revealed lower MBCs in M1. The pharmacological advantage of azithromycin accumulation in phagocytes and their role as chlamydial reservoirs remain uncertain. However, our data suggest possible therapeutic advantages of doxycycline in epithelial cells and we provide first evi-dence for an anti-C. abortus effect of nutlin-3 in M1.(c) 2022 Elsevier Inc. All rights reserved.
引用
收藏
页数:8
相关论文
共 16 条
  • [1] p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3
    Chappell, William H.
    Lehmann, Brian D.
    Terrian, David M.
    Abrams, Stephen L.
    Steelman, Linda S.
    McCubrey, James A.
    CELL CYCLE, 2012, 11 (24) : 4579 - 4588
  • [2] Therapeutic potential of the MDM2 inhibitor Nutlin-3 in counteracting SARS-CoV-2 infection of the eye through p53 activation
    Zauli, Giorgio
    AlHilali, Sara
    Al-Swailem, Samar
    Secchiero, Paola
    Voltan, Rebecca
    FRONTIERS IN MEDICINE, 2022, 9
  • [3] Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
    Arya, A. K.
    El-Fert, A.
    Devling, T.
    Eccles, R. M.
    Aslam, M. A.
    Rubbi, C. P.
    Vlatkovic, N.
    Fenwick, J.
    Lloyd, B. H.
    Sibson, D. R.
    Jones, T. M.
    Boyd, M. T.
    BRITISH JOURNAL OF CANCER, 2010, 103 (02) : 186 - 195
  • [4] Catalytic, enantioselective synthesis of stilbene cis-diamines: A concise preparation of (-)-Nutlin-3, a potent p53/MDM2 inhibitor
    Davis, Tyler A.
    Johnston, Jeffrey N.
    CHEMICAL SCIENCE, 2011, 2 (06) : 1076 - 1079
  • [5] Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
    A K Arya
    A El-Fert
    T Devling
    R M Eccles
    M A Aslam
    C P Rubbi
    N Vlatković
    J Fenwick
    B H Lloyd
    D R Sibson
    T M Jones
    M T Boyd
    British Journal of Cancer, 2010, 103 : 186 - 195
  • [6] Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3
    Huang, Baoying
    Vassilev, Lyubomir T.
    AGING-US, 2009, 1 (10): : 845 - 854
  • [7] Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation
    Mochizuki, Hiroyuki
    Goto-Koshino, Yuko
    Sato, Masahiko
    Fujino, Yasuhito
    Ohno, Koichi
    Tsujimoto, Hajime
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2012, 147 (3-4) : 187 - 194
  • [8] Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells
    Michaelis, M.
    Rothweiler, F.
    Barth, S.
    Cinatl, J.
    van Rikxoort, M.
    Loeschmann, N.
    Voges, Y.
    Breitling, R.
    von Deimling, A.
    Roedel, F.
    Weber, K.
    Fehse, B.
    Mack, E.
    Stiewe, T.
    Doerr, H. W.
    Speidel, D.
    Cinatl, J., Jr.
    CELL DEATH & DISEASE, 2011, 2 : e243 - e243
  • [9] MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway
    Zauli, Giorgio
    Rimondi, Erika
    Corallini, Federica
    Fadda, Roberto
    Capitani, Silvano
    Secchiero, Paola
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 (10) : 1621 - 1630
  • [10] Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells
    M Michaelis
    F Rothweiler
    S Barth
    J Cinatl
    M van Rikxoort
    N Löschmann
    Y Voges
    R Breitling
    A von Deimling
    F Rödel
    K Weber
    B Fehse
    E Mack
    T Stiewe
    H W Doerr
    D Speidel
    J Cinatl
    Cell Death & Disease, 2011, 2 : e243 - e243